NCT02621593View on ClinicalTrials.gov

Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD

NACompletedINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions
Dry Eye Syndromes
Interventions
DEVICE

M22-IPL

The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filters that will be used for this evaluation are filters blocking wavelengths of 560 and 595 nm.

Trial Locations (2)

78746

Dell Laser Consultants, Austin

90211

Gaster Eye Center, Beverly Hills

All Listed Sponsors
lead

Lumenis Be Ltd.

INDUSTRY

NCT02621593 - Feasibility of IPL for Reducing Dry Eye Symptoms Caused by MGD | Biotech Hunter | Biotech Hunter